Three patients with invasive fusarium infection in matinas biopharma's oral mat2203 compassionate/expanded use access program achieve complete clinical response

Bedminster, n.j., march 22, 2024 (globe newswire) -- matinas biopharma holdings, inc. (nyse american: mtnb), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (lnc) platform delivery technology, announces complete clinical response in three patients with serious invasive fusarium infection following treatment with mat2203, matinas' oral formulation of the potent antifungal amphotericin b. all three patients were enrolled in the company's compassionate/expanded use access program and were treated by marisa h. miceli, md, professor of medicine, specializing in fungal infections and transplant diseases, division of infectious diseases, internal medicine, at the university of michigan.
MTNB Ratings Summary
MTNB Quant Ranking